MedTrace Logo

Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain

NCT02974114 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-08-28

Study results available
· View outcomes & findings →

Summary

This parallel, assessor blind, placebo-controlled, stratified, randomized study will investigate the effects of everyday pain on cognition and mobility in otherwise healthy individuals.

Conditions

Interventions

DRUG

Paracetamol and caffeine

Test product containing 500 mg paracetamol and 65 mg caffeine

DRUG

Paracetamol

Test product containing 500 mg paracetamol

OTHER

Placebo

Placebo to match paracetamol 665mg sustained release tablets

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-02-06
Completion
2017-02-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974114 on ClinicalTrials.gov